Search results for " Models"

showing 10 items of 4240 documents

How to deal with Haplotype data: An Extension to the Conceptual Schema of the Human Genome

2016

[EN] The goal of this work is to describe the advantages of the application of Conceptual Modeling (CM) in complex domains, such as genomics. Nowadays, the study and comprehension of the human genome is a major challenge due to its high level of complexity. The constant evolution in the genomic domain contributes to the generation of ever larger amounts of new data, which means that if we do not manage it correctly data quality could be compromised (i.e., problems related with heterogeneity and inconsistent data). In this paper, we propose the use of a Conceptual Schema of the Human Genome (CSHG), designed to understand and improve our ontological commitment to the domain and also extend (e…

0301 basic medicinehaplotypesGeISHigher education0206 medical engineeringconceptual modelingLibrary science02 engineering and technologystatistical modelscomputer.software_genreGenomelcsh:QA75.5-76.95Conceptual schema03 medical and health sciencesExtension (metaphysics)Sociologybusiness.industryHaplotypeGeneral MedicineConceptual modelingStatistical models030104 developmental biologyHaplotypesGenetic diagnosisChristian ministryHuman genomelcsh:Electronic computers. Computer scienceData miningbusinessGenetic diagnosiscomputer020602 bioinformaticsgenetic diagnosis.
researchProduct

Humanization of the Blood-Brain Barrier Transporter ABCB1 in Mice Disrupts Genomic Locus - Lessons from Three Unsuccessful Approaches

2018

ATP-binding cassette (ABC) transporters are of major importance for the restricted access of toxins and drugs to the human body. At the body's barrier tissues like the blood-brain barrier, these transporters are highly represented. Especially, ABCB1 (P-glycoprotein) has been a priority target of pharmaceutical research, for instance, to aid chemotherapy of cancers, therapy resistant epilepsy, and lately even neurodegenerative diseases. To improve translational research, the humanization of mouse genes has become a popular tool although, like recently seen for Abcb1, not all approaches were successful. Here, we report the characterization of another unsuccessful commercially available ABCB1 …

0301 basic medicinehumanizationPET imaginglcsh:QR1-502Locus (genetics)ATP-binding cassette transporterComputational biologyBiologyBlood–brain barrierlcsh:Microbiology03 medical and health sciencesExon0302 clinical medicinemedicineCoding regionmouse modelsGenePromoterABCB1: ABCB13. Good healthOriginal Research Paper030104 developmental biologymedicine.anatomical_structureHumanized mouseP-gpABC transporter030217 neurology & neurosurgeryEuropean journal of microbiology and immunology
researchProduct

RNase H2 Loss in Murine Astrocytes Results in Cellular Defects Reminiscent of Nucleic Acid-Mediated Autoinflammation

2018

Aicardi-Goutières syndrome (AGS) is a rare early onset childhood encephalopathy caused by persistent neuroinflammation of autoimmune origin. AGS is a genetic disorder and >50% of affected individuals bear hypomorphic mutations in ribonuclease H2 (RNase H2). All available RNase H2 mouse models so far fail to mimic the prominent CNS involvement seen in AGS. To establish a mouse model recapitulating the human disease, we deleted RNase H2 specifically in the brain, the most severely affected organ in AGS. Although RNase H2δGFAPmice lacked the nuclease in astrocytes and a majority of neurons, no disease signs were apparent in these animals. We additionally confirmed these results…

0301 basic medicinelcsh:Immunologic diseases. AllergyMaleEncephalomyelitis Autoimmune ExperimentalAicardi–Goutières syndromeRNase PDNA damageImmunologyRibonuclease HFluorescent Antibody TechniqueAicardi-goutières Syndrome ; Cellular Senescence ; Dna Damage ; Interferon Signature ; Rnase H2BiologyNervous System MalformationsAutoimmune Diseases03 medical and health sciencesMiceAutoimmune Diseases of the Nervous SystemNucleic AcidsmedicineImmunology and Allergycellular senescenceAnimalsRibonucleaseNeuroinflammationCells CulturedOriginal ResearchInflammationMice KnockoutInnate immune systemBrainmedicine.diseaseMolecular biologyImmunohistochemistryDisease Models Animal030104 developmental biologymedicine.anatomical_structurePhenotypeinterferon signatureAstrocytesKnockout mousebiology.proteinAicardi–Goutières syndromeDNA damageFemalelcsh:RC581-607RNase H2BiomarkersAstrocyteFrontiers in Immunology
researchProduct

MARTX Toxin in the Zoonotic Serovar of Vibrio vulnificus Triggers an Early Cytokine Storm in Mice

2017

Vibrio vulnificus biotype 2-serovar E is a zoonotic clonal complex that can cause death by sepsis in humans and fish. Unlike other biotypes, Bt2 produces a unique type of MARTXVv (Multifunctional-Autoprocessive-Repeats-in-Toxin; RtxA13), which is encoded by a gene duplicated in the pVvBt2 plasmid and chromosome II. In this work, we analyzed the activity of this toxin and its role in human sepsis by performing in vitro, ex vivo, and in vivo assays. First, we demonstrated that the ACD domain, present exclusively in this toxin variant, effectively has an actin-cross-linking activity. Second, we determined that the whole toxin caused death of human endotheliocytes and monocytes by lysis and apo…

0301 basic medicinelcsh:QR1-502MicrobiologiaVibrio vulnificusmedicine.disease_causeMonocyteslcsh:MicrobiologysepsisVibrio vulnificusCells CulturedOriginal ResearchMice Inbred BALB CCell DeathVirulencebiologyqPCR arrayInfectious DiseasesHost-Pathogen InteractionsBacteris patògensCytokinesV. vulnificusFemaleMicrobiology (medical)Virulence FactorsBacterial ToxinsImmunologyVirulenceSerogroupMicrobiologyMicrobiology03 medical and health sciencesImmune systemMARTXIn vivomedicineAnimalsHumansVibrioToxinEndothelial Cellsbiology.organism_classificationmedicine.diseaseVirologyVibrioinfectionDisease Models Animal030104 developmental biologyInfecciógene expressionCytokine stormEx vivoFrontiers in Cellular and Infection Microbiology
researchProduct

The Monoclonal Antitoxin Antibodies (Actoxumab–Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium diffi…

2016

Antibiotics have significant and long-lasting impacts on the intestinal microbiota and consequently reduce colonization resistance against Clostridium difficile infection (CDI). Standard therapy using antibiotics is associated with a high rate of disease recurrence, highlighting the need for novel treatment strategies that target toxins, the major virulence factors, rather than the organism itself. Human monoclonal antibodies MK-3415A (actoxumab–bezlotoxumab) to C. difficile toxin A and toxin B, as an emerging non-antibiotic approach, significantly reduced the recurrence of CDI in animal models and human clinical trials. Although the main mechanism of protection is through direct neutraliza…

0301 basic medicinelcsh:QR1-502gut microbiomeGut floralcsh:MicrobiologyantibioticsMiceLactobacillusLongitudinal StudiesOriginal Researchbiologyactoxumab and bezlotoxumabMK-3415AAntibodies MonoclonalClostridium difficile3. Good healthAnti-Bacterial AgentsInfectious DiseasesTreatment Outcome16S rDNA amplicon sequencingVancomycinmedicine.drugMicrobiology (medical)030106 microbiologyImmunologyClostridium difficile toxin AColonisation resistanceC. difficile toxin antibodyMicrobiologyMicrobiology03 medical and health sciencesVancomycinClostridium difficile infectionimmune therapymedicineAnimalsClostridioides difficileAkkermansiabiology.organism_classificationAntibodies NeutralizingSurvival AnalysisGastrointestinal MicrobiomeDisease Models Animal030104 developmental biologyBayesian networksBezlotoxumabImmunologyClostridium InfectionsAntitoxinsBroadly Neutralizing AntibodiesFrontiers in Cellular and Infection Microbiology
researchProduct

Caenorhabditis elegans as an in vivo model to assess fucoidan bioactivity preventing Helicobacter pylori infection

2020

Currently, Helicobacter pylori is the unique biological carcinogenic agent. The search for antimicrobial alternatives to antibiotics against this pathogen has been categorized as a priority due to the drastic failure associated with current applied antibiotic therapy. The present study assessed the bioactive antimicrobial capability of fucoidan (“Generally Recognized as Safe” approval – European Commission December 2017) from different species of Phaeophyceae algae (Fucus vesiculosus, Undaria pinnatifida, Macrocystis pyrifera) against H. pylori. All the studied fucoidans showed bacteriostatic and bactericidal effects at the studied concentrations [5–100] μg ml−1 and exposure times [0–7 days…

0301 basic medicinemedicine.drug_classAntibioticsPhaeophytaMicrobiologyHelicobacter Infections03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNutraceuticalAnti-Infective AgentsIn vivoPolysaccharidesGenerally recognized as safemedicineAnimalsCaenorhabditis elegansPathogenbiologyHelicobacter pyloriFucoidanGeneral MedicineHelicobacter pyloribiology.organism_classificationAntimicrobial3. Good healthDisease Models Animal030104 developmental biologychemistry030220 oncology & carcinogenesisFood Science
researchProduct

IL-17 for therapy.

2017

The cytokine IL-17 is now a target for an array of therapeutic monoclonal antibodies supposed to treat a variety of inflammatory diseases. The forerunner Secukinumab, an IL-17A neutralizing antibody, is meanwhile approved as first-line treatments for moderate-to-severe plaque psoriasis, and as second-line treatment for psoriatic arthritis and ankylosing spondylitis. Ixekizumab and Brodalumab, both also targeting the IL-17 pathway, were also recently approved by the FDA for plaque psoriasis. Using mice overexpressing IL-17A in a tissue of choice, we showed that the ectopic expression of this cytokine in keratinocytes resulted in a spontaneous and very strong form of psoriasis-like dermatitis…

0301 basic medicinemedicine.drug_classBrodalumabDermatitisMice TransgenicDermatologyMonoclonal antibodymedicine.disease_causeAntibodies Monoclonal HumanizedBiochemistryAutoimmunity03 medical and health sciencesPsoriatic arthritisMice0302 clinical medicinePsoriasisMedicineAnimalsHumansPsoriasisSpondylitis AnkylosingMolecular Targeted TherapyMolecular BiologySkinbusiness.industryInterleukin-17Antibodies Monoclonalmedicine.diseaseIxekizumabDisease Models Animal030104 developmental biologyImmunologySecukinumabInterleukin 17business030215 immunologySignal TransductionJournal of dermatological science
researchProduct

Early reductive stress and late onset overexpression of antioxidant enzymes in experimental myocardial infarction.

2020

Reductive stress is defined as a pathophysiological situation in which the cell becomes more reduced than in the normal, resting state. It represents a disturbance in the redox state that is harmful to biological systems. Our aim was to study the occurrence of reductive stress in the early phases of experimental myocardial infarction and to determine the mechanisms leading to such stress using a swine model. During the ischemic period, we found a decrease in the oxidized to reduced glutathione ratio (GSSG/GSH) (0.7-0.3), in the lactate to pyruvate ratio (42.7-132.4), in protein glutathionylation (111.8-96.1), and in p38 phosphorylation (0.9-0.4). This was accompanied by a significant increa…

0301 basic medicinemedicine.medical_specialtyAntioxidantDisturbance (geology)Swinemedicine.medical_treatmentCellMyocardial InfarctionLate onsetBiochemistryAntioxidants03 medical and health sciencesInternal medicinemedicineAnimalsMyocardial infarctionchemistry.chemical_classification030102 biochemistry & molecular biologyResting state fMRIGeneral Medicinemedicine.diseasePathophysiologyDisease Models AnimalOxidative Stress030104 developmental biologyEndocrinologyEnzymemedicine.anatomical_structurechemistryFemaleFree radical research
researchProduct

Embryo multinucleation at the two-cell stage is an independent predictor of intracytoplasmic sperm injection outcomes.

2016

Objective To determine the prognostic impact of the nuclear status at the two-cell stage on intracytoplasmic sperm injection (ICSI) outcomes. Design Retrospective study. Setting Hospital. Patient(s) Only ICSI cycles with time-lapse monitoring of transferred embryos with known implantation/delivery data from November 2012 to December 2014 were included. A total of 2,449 embryos were assessed for multinucleation rates at the two- and four-cell stage, and 608 transferred embryos were studied for ICSI outcomes. Intervention(s) None. Main Outcome Measure(s) Implantation rate (IR) and live birth rate (LBR) according to the number of multinucleated blastomeres at the two-cell stage: none (Without-…

0301 basic medicinemedicine.medical_specialtyBlastomeresPregnancy Ratemedicine.medical_treatmentCleavage Stage OvumBiologyInseminationTime-Lapse ImagingIntracytoplasmic sperm injectionAndrology03 medical and health sciences0302 clinical medicinePregnancyRisk FactorsmedicineOdds RatioHumansEmbryo ImplantationSperm Injections IntracytoplasmicRetrospective StudiesGynecologyCell NucleusPregnancy030219 obstetrics & reproductive medicineChi-Square DistributionMicroscopy VideoObstetrics and GynecologyEmbryomedicine.diseaseEmbryo TransferEmbryo MammalianConfidence intervalEmbryo transferPregnancy rate030104 developmental biologyFertilityLogistic ModelsTreatment OutcomeReproductive MedicineInfertilityembryonic structuresMultivariate AnalysisFemaleLive birthLive BirthFertility and sterility
researchProduct

Alzheimer's disease: Only prevention makes sense

2018

Alzheimer's disease therapeutics is one of the most important endeavours in today's clinical investigation. Over more than 30 years of research, no disease-modifying treatment has been approved by either the FDA or the EMA to treat Alzheimer's disease. Recently, the evidence of pathological alterations in the brain tissue has been gathered showing that the signs of brain damage appear more than 20 years before the onset of Alzheimer's dementia. The major aim of this review is to underpin the idea that in Alzheimer's therapeutics, only prevention makes sense. It is difficult to visualise that would-be patients may be treated with endovenous administration of antibodies for several years to d…

0301 basic medicinemedicine.medical_specialtyClinical BiochemistryBrain damageDiseaseBiochemistryAsymptomaticAntioxidantsMice03 medical and health sciences0302 clinical medicineAlzheimer DiseaseAnimalsHumansVitamin EMedicineDementiaHealthy LifestyleTreatment FailureIntensive care medicinePathologicalNootropic AgentsAgedAged 80 and overClinical Trials as Topicbusiness.industryAntibodies MonoclonalCognitionGeneral MedicineMiddle Agedmedicine.diseaseClinical trialDisease Models Animal030104 developmental biologymedicine.symptombusiness030217 neurology & neurosurgeryMinimal cognitive impairmentEuropean Journal of Clinical Investigation
researchProduct